Prognostic utility of myocardial blood flow assessed by N-13 ammonia positron emission tomography in patients with idiopathic dilated cardiomyopathy

American Journal of Cardiology

Volumn 84, Issue 4, 1999, Pages 434-439

  Shikama, Nobuaki ^a   Himi, Toshiharu ^a   Yoshida, Katsuya ^b   Nakao, Motohiro ^a   Fujiwara, Masaki ^a   Tamura, Takashi ^a   Yamanouchi, Masato ^a   Nakagawa, Keiichi ^a   Kuwabara, Yoichi ^a   Toyozaki, Tetsuya ^a   Masuda, Yoshiaki ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIAC AGENT; CARDIOTONIC AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITROGEN 13;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; HEART MUSCLE BLOOD FLOW; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; VARIANCE;

ADULT; AGED; AMMONIA; BIOPSY; BLOOD FLOW VELOCITY; CARDIOMYOPATHY, DILATED; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; NITROGEN ISOTOPES; PROGNOSIS; RADIONUCLIDE VENTRICULOGRAPHY; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033566840     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00329-X     Document Type: Article

References (30)

1. Schelbert H.R. Metabolic imaging to assess myocardial viability. J Nucl Med. 35:1994;8S-14S.
2. Bonow R.O. Identification of viable myocardium. Circulation. 94:1996;2674-2680.
3. Eitman D., Al-Aouar Z., Kanter H.L., Dahl J.V., Kirsh M., Deeb G.M., Schwaiger M. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 20:1992;559-565.
4. Yoshida K., Gould K.L. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol. 22:1993;984-997.
5. Tamaki N., Kawamoto M., Takahashi N., Yonekura Y., Magata Y., Nohara R., Kambara H., Sasayama S., Hirata K., Ban T., Konishi J. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction comparison with stress thallium imaging . J Am Coll Cardiol. 22:1993;1621-1627.
6. DiCarli M.F., Davidson M., Little R., Khanna S., Mody F.V., Brunken R.C., Czernin J., Rokhsar S., Stevenson L.W., Laks H., Hawkins R., Schelbert H., Phelps M., Maddahi J. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 73:1994;527-533.
7. 13N ammonia and reoriented dynamic positron emission tomographic imaging. Circulation. 86:1992;1004-1017.
8. Muzik O., Beanlands R.S.B., Hutchins G.D., Mangner T.J., Nguyen N., Schwaiger M. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med. 34:1993;83-91.
9. Yoshida K., Mullani N., Gould L. Coronary flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med. 37:1996;1701-1712.
10. Kitsukawa S., Yoshida K., Mullani N., Nakagawa K., Shimada K., Takami A., Himi T., Masuda Y. Simple and Patlak models for myocardial blood flow measurements with nitrogen-13 ammonia and PET in man. J Nucl Med. 39:1998;1123-1128.
11. Parodi O., Maria R., Oltrona L., Testa R., Sambuceti G., Roghi A., Merli M., Belingheri L., Accinni R., Spinelli F., Pellegrini A., Baroldi G. Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. Circulation. 88:1993;509-522.
12. Neglia D., Parodi O., Gallopin M., Sambuceti G., Giorgetti A., Pratali L., Salvadori P., Michelassi C., Lunardi M., Pelosi G., Marzilli M., L'Abbate A. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. Circulation. 92:1995;796-804.
13. Doi Y., Chikamori T., Takata J., Yonezawa Y., Poloniecki J.D., Ozawa T., Mckenna W.J. Prognostic value of thallium-201 perfusion defects in idiopathic dilated cardiomyopathy. Am J Cardiol. 67:1991;188-193.
14. Juilliere Y., Marie P.Y., Danchin N., Gillet C., Paille F., Karcher G., Bertrand A., Cherrier F. Radionuclide assessment of regional differences in left ventricular wall motion and myocardial perfusion in idiopathic dilated cardiomyopathy. Eur Heart J. 14:1993;1163-1169.
15. Shiotani H., Yamabe H., Fukuzaki H. The clinical and prognostic significance of dipyridamole Tl-201 emission computed tomography in patients with dilated cardiomyopathy. Jpn Circ J. 51:1987;1016-1021.
16. Yoshida K., Endo M., Fukuda H., Kagaya A., Himi T., Masuda Y., Inagaki Y., Iinuma T., Yamasaki T., Tateno Y. Measurement of arterial tracer concentrations from cardiac PET images. J Comput Assist Tomogr. 19:1995;182-187.
17. 13N] ammonia in human and canine blood. J Nucl Med. 31:1990;163-167.
18. Schelbert H.R., Phelps M.E., Huang S.C., MacDonald N.S., Hansen H., Selin C., Kuhl D.E. N- 13 ammonia as an indicator of myocardial blood flow. Circulation. 63:1981;1259-1272.
19. Weiss M.B., Ellis K., Sciacca R.R., Johnson L.L., Schmidt D.H., Cannon P.J. Myocardial blood flow in congestive and hypertrophic cardiomyopathy relationship to peak wall stress and mean velocity of circumferential fiber shortening . Circulation. 54:1976;484-494.
20. Opherk D., Schwartz F., Mall G., Manthey J., Baller D., Kubler W. Coronary dilatory capacity in idiopathic dilated cardiomyopathy analysis of 16 patients . Am J Cardiol. 51:1983;1657-1662.
21. Nitenberg A., Foult J.M., Blanchet F., Zouioueche S. Multifactorial determinants of reduced coronary flow reserve after dipyridamole in dilated cardiomyopathy. Am J Cardiol. 55:1985;748-754.
22. Weismuller S., Czernin J., Sun K.T., Fung C., Phelps M.E., Schelbert H.R. Coronary vasodilatory capacity is impaired in patients with dilated cardiomyopathy. Am J Card Imaging. 10:1996;154-162.
23. Thomas J.A., Marks B.H. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 41:1978;233-243.
24. Leimbach W.N., Wallin B.G., Victor R.G., Aylward P.E., Sunlof G., Mark A.L. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 5:1986;913-919.
25. Hasking G.J., Esler M.D., Jennings G.L., Burton D., Korner P.I. Norepinephrine spillover to plasma in patients with congestive heart failure evidence of increased overall and cardiorenal sympathetic nervous activity . Circulation. 73:1986;615-621.
26. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., Simon A.B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
27. Benedict C., Shelton B., Johnstone D., Francis G., Greenberg B., Konstam M., Probstfield J.L., Yusuf S. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation. 94:1996;690-697.
28. Kaye D.M., Lambert G.W., Lefkovits J., Morris M., Jennings G., Esler M.D. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 23:1994;570-578.
29. Bach D.S., Beanlands R.S.B., Schwaiger M., Armstrong W.F. Heterogeneity of ventricular function and myocardial oxidative metabolism in nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 25:1995;1258-1262.
30. Mody F.V., Brunken R.C., Stevenson L.W., Nienaber C.A., Phelps M.E., Schelbert H.R. Differentiating cardiomyopathy of coronary artery disease from nonischemic cardiomyopathy utilizing positron emission tomography. J Am Coll Cardiol. 17:1991;373-383.